1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Delayed Xetra  -  05/26 11:38:55 am EDT
65.90 EUR   +3.32%
05:13aBAYER AG : Deutsche Bank keeps its Buy rating
MD
02:18aBAYER AG : Bernstein reaffirms its Buy rating
MD
05/25Bayer CropScience's Net Profit Soars in Fiscal Q4
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/26/2022 Date
63.74(c) 64.47(c) 63.29(c) 63.78(c) 65.9(c) Last
2 625 237 2 202 703 2 582 622 1 738 849 3 149 253 Volume
+0.54% +1.15% -1.83% +0.77% +3.32% Change
More quotes
Estimated financial data (e)
Sales 2022 47 605 M 51 067 M 51 067 M
Net income 2022 4 996 M 5 360 M 5 360 M
Net Debt 2022 33 100 M 35 507 M 35 507 M
P/E ratio 2022 13,0x
Yield 2022 3,35%
Sales 2023 48 921 M 52 479 M 52 479 M
Net income 2023 5 667 M 6 079 M 6 079 M
Net Debt 2023 30 650 M 32 879 M 32 879 M
P/E ratio 2023 11,5x
Yield 2023 3,70%
Capitalization 64 742 M 69 450 M 69 450 M
EV / Sales 2022 2,06x
EV / Sales 2023 1,95x
Nbr of Employees 100 753
Free-Float 100,0%
More Financials
Company
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (45.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (41.6%) : intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc. ; - OTC... 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
Ratings of Bayer AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BAYER AG
05:13aBAYER AG : Deutsche Bank keeps its Buy rating
MD
02:18aBAYER AG : Bernstein reaffirms its Buy rating
MD
05/25Bayer CropScience's Net Profit Soars in Fiscal Q4
MT
05/24Bayer Commits To UN's Zero Hunger Private Sector Pledge
MT
05/23Bayer's Kerendia Found to Reduce Hospitalization for Heart Failure in Exploratory Post ..
MT
05/23BAYER : New data support renal and cardiovascular benefits of Kerendia™ (finerenone)..
PU
05/23Bayer's Xarelto Shows Long-Term Effect in Heart Disease Patients
MT
05/23BAYER : Two large Xarelto™ studies support effectiveness of dual pathway inhibition ..
PU
05/20Fitch Maintains Bayer's Rating, Stable Outlook on Strong Operating Performance
MT
05/19Atara Biotherapeutics, Bayer Collaboration on CAR T-cell Therapies to be Terminated in ..
MT
05/19Atara Biotherapeutics, Inc. Receives Written Notice of Termination from Bayer AG of the..
CI
05/19BAYER AG : Buy rating from UBS
MD
05/19Bayer Secures Authorization for Chronic Heart Failure Therapy in China
MT
05/17Bayer's New Therapeutic Option to Reduce Risk of Cardiovascular Deaths and Repeated Hos..
CI
05/16China's LongPing to launch Brazil sorghum seed next year
RE
More news
News in other languages on BAYER AG
12:24pMÄRKTE EUROPA/Käufe zu Christi Himmelfahrt - Einzelhandelsaktien sehr fest
11:57aXETRA-SCHLUSS/DAX fest - Aufwärtsbewegung gewinnt an Breite
10:26aMÄRKTE EUROPA/Aufwärts - Wall Street sorgt für neuen Anschub
08:27aAKTIEN FRANKFURT : Dax baut Gewinne etwas aus
06:45aMÄRKTE EUROPA/Aktien an Christi Himmelfahrt mit leichten Gewinnen
More news
Analyst Recommendations on BAYER AG
More recommendations
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 65,90 €
Average target price 77,65 €
Spread / Average Target 17,8%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG35.70%66 908
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530